Sunday , July 25 2021

Cell cells transplanted in a patient's brain in Japan



This is the first world that gives hope to people with Parkinson's disease. Researchers at Kyoto University, Japan, said on Friday, November 9th, in a statement that they successfully transplanted 2.4 million iPS stem cells into the left brain of a patient with Parkinson's. "stimulated multi-drug cell cells" or, in French cells, stimulated multi-drugs).

The operation, last month, lasted for three hours, said the medical team. The patient, a man in his half, was well tolerated. He will now be under supervision for two years. If a problem does not appear within six months, doctors will implant 2.4 million additional cell cells, at this time on the right hand side of the patient's brain.

Multifunctional stem cells

The second most common neurodegenerative disease of the nervous system after Alzheimer's disease, Parkinson's disease affects about 200,000 people in France and more than one million in Europe: 8,000 new cases are reported annually in France. According to the United States Parkinson's Disease Institute, the world has 10 million Parkinson's patients.

Having characterized by an increasing loss of brain neurons that secrete dopamine, Parkinson's disease is increasingly causing loss of mobile control and other motor symptoms such as rest digestion and body stiffness. Currently, treatments that provide dopamine or imitate its deed are "recovering symptoms, but without slowing down the sequence of the disease," said the Parkinson's Disease Foundation.

This new treatment with iPS cell cells by healthy donors offers new hope for patients. Indeed, the latter has a difference of multi-drug: by transplanting to the brain, in a certain place, they should be able to transform into dummamine-producing neurons, a related neuro-transmitter with motor skills management.

A clinical trial was published on seven patients

Probably this final dissertation by Japanese scientists is not the last one. Last July, Kyoto University announced that a clinical trial would be launched with seven participants aged 50 to 69. "I talk about the patients for their brave and decisive participation," said Professor Jun Takahashi, quoted on Friday by the NHK public television channel.

This clinical trial itself has based on an experiment performed on faucets with human cell cells, and was reported in an article in Nature magazine in August 2017. According to the researchers, This transplant has improved Capacity Parkinson's primaries make movements. The survival of graffiti cells, through injection to the brain of primates, was observed for two years without a tumor appearance.

However, it is necessary to keep it because it is not enough that the transplant is good for it to be functional. This is shown by cell cell cell transplants, whose experiments have been happening for years with a very modest, very practical result. All the problems will not be solved with transplant but hopefully the researchers and medications will move on.

Are you interested in this topic? Let's talk on our forum!


Source link